VENUS REMEDIES LIMITED Financial Ratios
VENUSREM · Healthcare · Current price ₹1,770
P/E ratio
23.0x
P/B ratio
3.5x
ROE
16.8%
ROCE
22.0%
Debt / Equity
0.02
Dividend yield
0.6%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 23.0x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 3.5x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 16.8% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 22.0% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.02 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with VENUS REMEDIES LIMITED's latest numbers.
VENUS REMEDIES LIMITED profitability
VENUS REMEDIES LIMITED generates a return on equity of 16.8% and a return on capital employed of 22.0%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.02 and a P/E of 23.0x, VENUS REMEDIES LIMITED is conservatively financed. Our overall business-quality score for the company is 5.2 / 10.
Understand the ratios
More on VENUS REMEDIES LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.